Kuros Biosciences AG, CH0325814116

Kuros Biosciences AG, CH0325814116

23.11.2022 - 07:04:25

Kuros Biosciences Completes Enrollment of Randomized Stage?of Phase 2 Trial for Fibrin-PTH

For further information, please contact:

Kuros Biosciences AG? Michael Grau Chief Financial Officer t: +41 44 733 47 47 e:?michael.grau@kurosbio.com LifeSci Advisors? HansSandya von der Weid Investors t: +41 78 680 0538 e:?svonderweid@lifesciadvisors.com

About Fibrin-PTH (KUR-113) Fibrin-PTH (KUR-113) consists of a natural fibrin-based healing matrix with an immobilized targeted bone growth factor (truncated human parathyroid hormone (PTH) analog. Fibrin-PTH (KUR-113) is designed to be applied directly into and around an intervertebral body fusion device as a gel, where it polymerizes in situ. Fibrin-PTH (KUR-113) functions via the well-established mechanism of action of parathyroid hormone; has been demonstrated in animal models of spinal fusion to be comparable to rhBMP-2; and has been shown in preclinical studies to be easy to use and ideal for open or minimally invasive techniques1*. The safety & efficacy of Fibrin-PTH (KUR-113) has not yet been evaluated for spinal fusion in humans.?

About Spinal Fusion Lumbar fusion surgery is designed to create solid bone between adjoining vertebrae of the spine, eliminating any movement between the bones. Spinal fusion may be recommended for conditions such as spondylolisthesis, degenerative disc disease or recurrent disc herniations. The goal of fusion surgery is to reduce pain and nerve irritation. Surgeons perform lumbar fusion using several techniques. One such technique - Transforaminal Lumbar Interbody Fusion (TLIF) - is used to stabilize the spinal vertebrae. This definition is adapted from www.spine-health.com. It is estimated that the orthobiology market for spinal fusion is growing to $2.2 billion in 2030, while currently over 800,000 spinal fusion procedures are performed annually in the US & EU.

About Kuros Biosciences Kuros Biosciences is a fast-growing leader in the development of spinal fusion biologics that ease the burden of back pain. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange. ?The company?s first commercial product, MagnetOs, is a unique synthetic bone graft that has already been used successfully across three continents and in over 10,000 spinal fusion surgeries. The next candidate in the Kuros pipeline is Fibrin-PTH ? the first drug-biologic combination for interbody spinal fusions, currently undergoing a Phase 2 clinical trial in the U.S. For more information on the company, its products and pipeline, visit kurosbio.com.

Forward Looking Statements This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words ?will? or ?expect? or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

1. Data on file *Results from in vivo laboratory testing may not be predictive of clinical experience in humans.?

End of Media Release

Language: English Company: Kuros Biosciences AG Wagistrasse 25 8952 Schlieren

Switzerland Phone: +41 44 733 4747 Fax: +41 44 733 4740 E-mail: info@kurosbio.com Internet: www.kurosbio.com ISIN: CH0325814116 Valor: 32581411 Listed: SIX Swiss Exchange EQS News ID: 1494157 ? End of News EQS News Service

1494157??23.11.2022?CET/CEST

@ dgap.de